The Osteoporosis Paradox: The Neglected Disease
|A symposium in conjunction with the 2nd International Meeting on Social and Economic Aspects of Osteoporosis and Bone Disease, Liège, Belgium, 7 December 2000
J.Y. REGINSTER, PH.D., M.D. is Professor of Epidemiology and Public Health, University of Liege, Liege, Belgium, and Head, University Center for Investigation in Bone and Articular Cartilage Metabolism, University of Liege. Prof. Reginster is also Director, WHO Collaborating Center for Public Health Aspects of Rheumatic Disorders (Non communicable diseases), and Adjunct Professor of Medicine: Georgetown University Medical Center, Washington D.C. USA.
His fields of interest include metabolic bone diseases, epidemiology, prevention and treatment of postmenopausal osteoporosis, pathophysiology of osteoporosis and osteoarthritis, diagnosis and screening procedures for osteoporosis and osteoarthritis, public health, health economics, pharmacoepidemiology, quality of life and health policies.
He has published more than 400 scientific articles in such publications as Lancet, Journal of Clinical Investigation, Annals of Internal Medicine, Arthritis and Rheumatism, Annals of Rheumatic Diseases and the Journal of Bone and Mineral Research, and is the author of more than 60 books or book chapters.
Prof. Reginster is also Executive Secretary of the International Osteoporosis Foundation and the Belgian Group for Clinical and Educational Development of Bone Diseases, and serves on a variety of editorial boards, including the European Journal of Physical Medicine and Rehabilitation, Osteoarthritis and Cartilage, Osteoporosis International, and Clinical Rheumatology (Deputy Editor).
PIERRE D. DELMAS, M.D., PH.D. is Professor of Medicine and Rheumatology at the Université Claude Bernard of Lyon, France. He is director of the INSERM Research Unit 403 on Pathophysiology of Osteoporosis at the Hôpital Edouard Herriot of Lyon. INSERM is the French National Institute for Medical Research.
Prof. Delmas and his research group have developed new markers of bone metabolism, such as osteocalcin and pyridinoline crosslinks that have been shown to be useful in the clinical investigation of osteoporosis. He directs basic and clinical research programs in the field of metabolic bone diseases with a special interest for osteoporosis and metastatic bone disease. As a rheumatologist, he is also conducting research activities in osteoarthritis and non steroidal anti inflammatory agents.
He has authored more than 400 articles and book chapters in international scientific journals. He is the Associate Editor of the journals Osteoporosis International, and Bone. As the President of the Board of the International Osteoporosis Foundation, Professor Delmas has been actively involved in the development of educational programs on osteoporosis.
MARY ANDERSON is Executive Director, International Osteoporosis Foundation (IOF), Swiss Executive Office, Hofstetten, Switzerland. Ms. Anderson has been a leader of the social movement that has put osteoporosis on the public agenda. She has helped to build IOF from a small, European-oriented group to a significant international network. IOF has generated public and governmental awareness of osteoporosis and helped patient societies in some 60 countries provide effective education and treatment to people at risk from the disease.
Formerly Executive Director of EFFO European Foundation for Osteoporosis, Mary Anderson was invited in 1998 to direct the International Osteoporosis Foundation (IOF), an umbrella organization which was formed when EFFO and the International Federation of Societies for Skeletal Diseases merged. She has managed the evolution of IOF, helped to define its governance model, supported the national societies in their capacity building efforts, and became an international spokeswoman for osteoporosis. IOF now counts 118 member societies from 65 countries, an increase of more than 60% since its founding.
Mary was one of the architects of the Report on Osteoporosis in the European Community the first European Community report which deals with a specific disease which has catalyzed significant government lobbying efforts throughout Europe. She was a principal organizer of the launch of this report, and obtained co-sponsorship of the World Health Organization (WHO) for this report and for World Osteoporosis Day.
She is also responsible for organizing the annual World Wide Conferences of Osteoporosis Patient Societies, and has developed mutually-beneficial partnerships with groups as diverse as pharmaceutical companies, the European Community, Business and Professional Women, the Bone and Joint Decade, where she serves on the International Steering Committee, and WHO.
Back to overview